Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
-0.28 (-0.85%)
Aug 18 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 32.65 - 32.97
52 week 29.83 - 35.38
Open 32.91
Vol / Avg. 0.00/16.79M
Mkt cap 194.55B
P/E 23.80
Div/yield 0.32/3.92
EPS 1.37
Shares 5.95B
Beta 1.00
Inst. own 71%
Oct 30, 2017
Q3 2017 Pfizer Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 13, 2017
Pfizer Inc at Morgan Stanley Healthcare Conference - 9:55AM EDT - Add to calendar
Aug 1, 2017
Q2 2017 Pfizer Inc Earnings Call - Webcast
Aug 1, 2017
Q2 2017 Pfizer Inc Earnings Release
Jun 15, 2017
Basilea Pharmaceutica AG Announces License Agreement With Pfizer For Antifungal Cresemba
Jun 14, 2017
Pfizer Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 9, 2017
Pfizer Inc Conference Call to provide Update on Oncology Business and to Review ASCO Data Presentations - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '17) 2016
Net profit margin 23.85% 13.68%
Operating margin 31.09% 17.05%
EBITD margin - 38.66%
Return on average assets 7.31% 4.26%
Return on average equity 21.10% 11.59%
Employees 96,500 -
CDP Score - B


235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 59
Bio & Compensation  - Reuters
Albert Bourla Group President - Pfizer Innovative Health
Age: 55
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 58
Bio & Compensation  - Reuters
John D. Young Group President - Pfizer Essential Health
Age: 52
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 55
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 61
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Kirsten Lund-Jurgensen Executive Vice President, President - Pfizer Global Supply
Age: 57
Bio & Compensation  - Reuters